Amundi Raises Stock Holdings in Xencor, Inc. (NASDAQ:XNCR)

Amundi raised its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 225.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,380 shares of the biopharmaceutical company's stock after purchasing an additional 24,494 shares during the period. Amundi owned 0.05% of Xencor worth $829,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of XNCR. GAMMA Investing LLC increased its stake in shares of Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 508 shares in the last quarter. KBC Group NV increased its stake in shares of Xencor by 63.5% in the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 1,213 shares in the last quarter. Quarry LP increased its stake in shares of Xencor by 111.4% in the third quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock worth $80,000 after purchasing an additional 2,108 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock worth $93,000 after purchasing an additional 1,337 shares in the last quarter. Finally, Rockefeller Capital Management L.P. purchased a new position in shares of Xencor in the third quarter worth about $205,000.

Analyst Upgrades and Downgrades

XNCR has been the subject of several recent research reports. StockNews.com downgraded shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Piper Sandler upgraded shares of Xencor from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. Finally, Wells Fargo & Company cut their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Xencor presently has an average rating of "Moderate Buy" and an average price target of $34.38.

Remove Ads

Xencor Price Performance

Xencor stock traded down $0.27 during mid-day trading on Friday, hitting $13.20. 2,567,821 shares of the company traded hands, compared to its average volume of 571,664. Xencor, Inc. has a one year low of $12.54 and a one year high of $27.24. The stock has a market cap of $930.10 million, a price-to-earnings ratio of -4.13 and a beta of 0.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The stock has a fifty day moving average price of $16.36 and a 200-day moving average price of $20.30.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. On average, equities analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.